Skip to main content

Table 1 Baseline demographics and clinical characteristics (N = 124)

From: The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis

Characteristics   
Gender N % of sample
 Male 84 67.7
 Female 40 32.3
Antipsychotic drug naïve 64 51.6
Alcohol use last 6 months   
 None 17 13.7
 Misuse 15 12.1
Illicit drug use last 6 months   
 None 82 66.1
 Use/ Misuse 25 20.2
Current tobacco smoking 64 51.6
Diagnosisa   
 Schz and related 67 57.8
 Acute 8 6.9
 Drug-induced 21 18.1
 Affective 11 9.5
 Rest 9 7.8
  Mean SD/ range
Age 33.5 12.4/18–65
Body Mass Index 23.5 4.6/ 15.8–40.3
Years of Education 12.5 2.7/ 8–22
PANSS Total 73.4 11.9/ 45–98
PANSS Positive 20.1 4.1/ 12–30
PANSS Negative 19.0 6.9/ 7–38
PANSS General 34.3 6.4/ 20–56
CDSS 6.2 5.0/ 0–23
GAF-F 30.5 4.9/ 18–45
CGI 5.2 0.6/ 4–6
RBANS t-score 37.8 7.7/ 20.2–58.8
  1. N number of patients, SD standard deviation; Antipsychotic drug naive = No life-time exposure to antipsychotic drugs before index admission; Misuse = Misuse or Dependence according to the Clinical Drug and Alcohol Use Scales (CDUS/CAUS), patients with no illicit drug use could be included in the category alcohol use last 6 months; Schz and related = Schizophrenia and related disorders: Schizophrenia, schizo-affective disorder, acute polymorphic psychotic disorder with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder, delusional disorder; Acute = Acute psychosis other than those categorized under Schz and related; Affective = Affective psychosis; Rest = Miscellaneous psychotic disorders. All diagnoses are according to ICD-10; PANSS the Positive and Negative Syndrome Scale, CDSS the Calgary Depression Scale for Schizophrenia, GAF-F the Global Assessment of Functioning, split version, Functions scale, CGI the Clinical Global Impression, severity of illness scale, RBANS the Repeatable Battery for the Assessment of Neuropsychological Status
  2. aPatients with missing diagnoses are not included in the list